يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Ottolini, Stefano"', وقت الاستعلام: 0.74s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Tirofiban Positively Regulates β1 Integrin and Favours Endothelial Cell Growth on Polylactic Acid Biopolymer Vascular Scaffold (BVS)

    المؤلفون: Giordano, ArturoAff1, Aff2, Romano, Simona, Corcione, NicolaAff1, Aff2, Frati, Giacomo, Zoccai, Giuseppe BiondiAff4, Aff5, Ferraro, PaoloAff1, Aff2, Messina, StefanoAff1, Aff2, Ottolini, Stefano, Romano, Maria FiammettaAff3

    المصدر: Journal of Cardiovascular Translational Research. 11(3):201-209

    Find this article in full text from Springer Verlag. Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

    المؤلفون: Breccia, Massimo, Pregno, Patrizia, Spallarossa, Paolo, Arboscello, Eleonora, Ciceri, Fabio, Giorgi, Mauro, Grossi, Alberto, Mallardo, Mario, Nodari, Savina, Ottolini, Stefano, Sala, Carla, Tortorella, Giovanni, Rosti, Gianantonio, Pane, Fabrizio, Minotti, Giorgio, Baccarani, Michele

    المصدر: Annals of Hematology. April 2017 96(4):549-558

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    The effects of felodipine and amlodipine on glucose and lipid metabolism in patients affected by non—insulin-dependent diabetes mellitus and hypertension: a comparative, randomized, parallel-group study

    المؤلفون: Baggio, Edoardo, Maraffi, Franco, Montalto, Claudio, Conti, Danilo, Ravera, Elisabetta, Ottolini, Stefano, Gandini, Renato

    المصدر: In Current Therapeutic Research 1995 56(10):1050-1058

    Full Text Finder
    أضف إلى المفضلة
  4. 4
    Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

    المؤلفون: Giovanni Tortorella, Massimo Breccia, Fabrizio Pane, Patrizia Pregno, Fabio Ciceri, Carla Sala, Giorgio Minotti, Michele Baccarani, Mauro Giorgi, Paolo Spallarossa, Alberto Grossi, Stefano Ottolini, Savina Nodari, Mario Mallardo, Eleonora Arboscello, Gianantonio Rosti

    المساهمون: Breccia, Massimo, Pregno, Patrizia, Spallarossa, Paolo, Arboscello, Eleonora, Ciceri, Fabio, Giorgi, Mauro, Grossi, Alberto, Mallardo, Mario, Nodari, Savina, Ottolini, Stefano, Sala, Carla, Tortorella, Giovanni, Rosti, Gianantonio, Pane, Fabrizio, Minotti, Giorgio, Baccarani, Michele

    مصطلحات موضوعية: medicine.medical_specialty, medicine.drug_class, Antineoplastic Agents, 030204 cardiovascular system & hematology, Assessment, Chronic myeloid leukaemia, Tyrosine-kinase inhibitor, Follow-Up Studie, Food and drug administration, Antineoplastic Agent, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Cardiovascular Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Humans, Disease management (health), Intensive care medicine, Imidazole, Expert Testimony, Risk management, Clinical Trials as Topic, Modalities, business.industry, Risk Factor, Ponatinib, Imidazoles, Disease Management, Hematology, General Medicine, Cardiovascular risk, Management, Pyridazines, chemistry, Cardiovascular Diseases, 030220 oncology & carcinogenesis, Expert opinion, Physical therapy, business, Pyridazine, Follow-Up Studies, Human

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ece7c6a4b140a0e44e19494c2dce5eba
    http://hdl.handle.net/11588/680828

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء